Aderamastat

Aderamastat (FP-025) is an orally active, selective MMP-12 inhibitor. Aderamastat provides protection against house dust mite (HDM) -sensitized allergic asthma. Aderamastat can be used in the research of respiratory diseases, including chronic inflammatory airway diseases and pulmonary fibrosis[1][2][3].

Product Specifications

CAS Number

[877176-23-3]

Product Name Alternative

FP-025

UNSPSC

12352005

Target

MMP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/aderamastat.html

Purity

98.16

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1NC(C(C2=C(SC3=CC=C(C=C3)OCC4=CC(C)=CC=C4)C=CO2)N1)=O

Molecular Formula

C21H18N2O4S

Molecular Weight

394.44

References & Citations

[1]Abd-Elaziz KS, et al. Validation of a method for the determination of Aderamastat (FP-025) in K2EDTA human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Sep 15;1245:124244.|[2]Abd-Elaziz K, et al. First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects. Clin Drug Investig. 2021 Jan;41 (1) :65-76. |[3]Ravanetti L, et al. Efficacy of FP-025: A novel matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma. Allergy. 2023 Feb;78 (2) :559-562.